Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. (OTC: CUBT) is a development-stage biomedical company focused on novel therapies for rare diseases, with programs in degenerative eye disease, infectious disease, and neuro-oncology. The CUBT news feed on this page aggregates company-issued updates and other coverage so readers can follow how its pipeline and strategy evolve over time.
Recent news has highlighted Curative Biotech’s emphasis on its degenerative eye disease platform, built on a worldwide exclusive license from the National Eye Institute (NEI) at the NIH. Articles cover progress with its metformin-based ophthalmic reformulation for intermediate and late-stage Age-Related Macular Degeneration (AMD), including completion of IND-enabling toxicology work, a planned first-in-human trial under a CRADA with the NEI, and the filing of a PCT patent application for an ophthalmic formulation capable of delivering metformin to the choroid, RPE, and retina.
News items also describe corporate and strategic developments, such as the establishment of Curative Biotech Japan K.K. to support licensing and asset acquisitions in Japan, the engagement of Golden Eagle Capital Advisors, Inc. as exclusive agent and strategic advisor, and updates on capital structure, including withdrawal of a planned S-1 offering and revisions to a proposed reverse stock split. Governance-focused releases detail the nomination or appointment of independent directors with ophthalmology and biotechnology experience and the creation of a Clinical Development Committee of the Board.
Investors and observers can use this page to review Curative Biotech’s announcements on clinical planning, licensing strategy, veterinary ophthalmology initiatives in canine retinal diseases, and capital markets intentions, all in one place. Bookmark this feed to quickly reference historical and ongoing CUBT news as the company advances its development-stage programs.
Curative Biotechnology Inc. (OTC: CUBT) has appointed Lawrence S. Zaslow as an independent director, enhancing its Board of Directors. Zaslow, a co-founder of BioTheryX, Inc., brings extensive experience in strategic planning, capital raising, and corporate development. His leadership contributed to BioTheryX's $100 million financing round. Curative Biotech focuses on novel treatments for rare diseases, with ongoing programs in infectious disease, neuro oncology, and degenerative eye disease, including its pipeline candidates IMT504, CURB906, and a reformulated Metformin for Age-Related Macular Degeneration.
Curative Biotechnology Inc. (CUBT) announced the appointment of Cary Sucoff as an independent director on May 12, 2022. Sucoff brings over 35 years of experience in legal and securities sectors, having participated in financing for more than 100 public and private companies. His expertise encompasses legal compliance, corporate strategy, and capital markets. Sucoff is also involved with several healthcare and biotech firms, enhancing Curative Biotech's financial governance and oversight capabilities.
Curative Biotechnology Inc. (CUBT) has appointed Cary Sucoff as an independent director, enhancing its financial expertise amidst its focus on rare disease treatments. With over 35 years in legal and securities sectors, Sucoff brings extensive experience from his involvement in financing numerous public and private companies. He currently advises several healthcare firms and has held leadership roles in multiple committees across various boards. CUBT continues to develop innovative therapies, including treatments for infectious diseases and degenerative eye diseases.
Curative Biotechnology, Inc. (CUBT) announced a collaboration with the National Eye Institute (NEI) under a Cooperative Research and Development Agreement (CRADA) to advance its metformin formulation for treating Age-Related Macular Degeneration (AMD). The company is conducting a Good Laboratory Practice (GLP) toxicology study to evaluate the formulation's tolerability, pharmacokinetics, and ocular tissue distribution, crucial for an FDA Investigational New Drug (IND) filing. This study involves comprehensive ocular assessments by certified specialists.
Curative Biotechnology (OTC: CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) on March 21, 2022. This collaboration aims to evaluate Curative's proprietary ocular metformin formulation for treating Age-Related Macular Degeneration (AMD), a leading cause of vision loss. The CRADA will last three years, with research under the supervision of Dr. Emily Chew from NEI, potentially addressing unmet medical needs in AMD therapy.
Curative Biotechnology (CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) to study its ocular metformin formulation for treating Age-Related Macular Degeneration (AMD). The agreement, effective for three years, aims to address the unmet therapeutic needs for AMD, a leading cause of vision loss. Under the leadership of Dr. Emily Chew, the collaboration will explore clinical evaluations of this novel therapy.
Curative Biotechnology (CUBT) has advanced its metformin eye drop formulations into ocular tolerance evaluation, marking a critical step toward human clinical trials. The studies will assess tolerability and pharmacokinetics, focusing on safety and ocular tissue distribution. This research will support future Good Laboratory Practice toxicology studies required for an Investigational New Drug (IND) filing. As part of the evaluation, metformin's plasma concentration will also be measured to ensure systemic safety. The company's innovative approach targets rare diseases, aiming for accelerated development paths.
Curative Biotechnology (OTC: CUBT) has announced the initiation of ocular tolerance evaluations for various metformin eye drop formulations, marking a progression towards human clinical trials. These studies will assess tolerability and pharmacokinetics, crucial for optimizing the formulation and ensuring safety for future IND filing. The research includes monitoring metformin plasma concentration to evaluate systemic exposure, alongside ophthalmic examinations and histopathological analysis. This advancement aligns with the company's focus on developing novel treatments for rare diseases.
Curative Biotechnology (CUBT) announced Dr. Catherine Sohn's appointment as a Special Advisor to its Board of Directors on October 12, 2021. Dr. Sohn, with over 30 years of biopharmaceutical experience, will oversee the company's infectious disease and macular degeneration programs. Paul Michaels, Chairman, emphasized her strategic background in vaccine development, particularly for the next-generation COVID-19 vaccine targeting kidney failure patients. This appointment aims to accelerate Curative's novel treatments for rare diseases and conditions, including a promising rabies therapeutic.
Curative Biotechnology (CUBT) has expanded its licensing agreement with Mid-Atlantic BioTherapeutics to include the development of a next-generation COVID-19 vaccine targeting kidney failure patients. This initiative addresses the need for tailored vaccines for immunocompromised individuals, who often have poor responses to existing vaccines. Curative Biotech also holds worldwide rights to develop IMT504 for treating symptomatic rabies, with orphan drug designation received in the US. The company aims to enhance its clinical development team in upcoming announcements.
FAQ
What is the current stock price of Curative Biotechnology (CUBT)?
What is the market cap of Curative Biotechnology (CUBT)?
